Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases in the United States (1) . Its prevalence has been continuously rising over the past decade in both children and adults (2, 3) , and it is estimated that 17-35% of US adults may have NAFLD (4) . It consists of a spectrum of liver diseases, ranging from benign steatosis to steatohepatitis (NASH) with or without significant fibrosis, cirrhosis, and liver failure (1) . Subjects with NAFLD have a higher prevalence of obesity, insulin resistance, diabetes mellitus, dyslipidemia (5) , and, most importantly, atherosclerosis. Indeed, cardiovascular disease is the most common cause of death in these subjects (6) .
The definition of NAFLD requires that a person not consume significant amounts of alcohol, but what constitutes significant alcohol consumption for defining NAFLD remains unclear. The published literature has used varying thresholds of alcohol consumption in defining NAFLD, ranging from ≤1 drink (14 g ) per day to <30 g per day on average (6) (7) (8) (9) (10) . Aside from the quantity of alcohol consumed, other factors such as gender, timing (ongoing vs. remote), and the duration of alcohol consumption (short term vs. chronic) have not been routinely considered in defining NAFLD.
Once a patient is diagnosed with NAFLD, total or near-total abstinence is generally recommended, presumably to avoid the harmful effects of alcohol on the underlying liver disease (11) . However, no studies have systematically examined the effect of various levels of alcohol consumption on the natural history of NAFLD. Three pertinent questions in this context are (i) what is the effect of alcohol consumption on the prevalence of NAFLD in high-risk populations (obese or with metabolic syndrome); (ii) what is the effect of alcohol consumption on underlying liver disease in people already diagnosed with NAFLD; and (iii) is there cardiovascular benefit to alcohol consumption in people with NAFLD?
The literature suggests that the effect of alcohol on liver disease in populations at high risk for NAFLD may indeed depend on the levels of alcohol consumption (heavy vs. light or moderate). Three cross-sectional studies suggested a synergistic effect between alcohol consumption and excess body weight (9, 12) . In the Dionysos Study, obese people who drank heavily (defined as consumption of 30 g of alcohol per day or 100 kg of alcohol over a lifetime) had a significantly higher prevalence of hepatic steatosis than non-obese heavy drinkers (odds ratio (OR) 2.8, 95% confidence interval (CI) 1.4-7.1) and non-obese non-drinkers (OR 5.8, 95% CI 3.2-12.3) (9) . The findings of the population-based Third National Health and Nutrition Examination Survey (NHANES III) showed that the likelihood of hepatic injury was higher at increasing body weight even when the level of alcohol consumption was as low as two drinks per day (12) . In this report by Ruhl and Everhart, the prevalence of elevated aminotransferase levels increased with increasing body mass index for each alcohol-drinking level (P < 0.05). For example, in people with alcohol consumption higher than two drinks per day, the multivariate-adjusted logistic regression odds ratio for elevated It is generally recommended that patients with nonalcoholic fatty liver disease (NAFLD) not consume alcohol. However, because these patients are at increased cardiovascular risk, and light to moderate alcohol consumption may have hepatic benefits in people with or at risk for NAFLD, this recommendation may be ill-advised. We reviewed the literature on alcohol consumption and NAFLD and conclude that (i) heavy consumption has many harmful effects, including those on the liver, and should be discouraged whether a person has NAFLD or not; (ii) it is unknown whether cardiovascular and metabolic benefits of light to moderate consumption observed in the general population extend to those with NAFLD; (iii) epidemiological and cohort studies suggesting that light to moderate drinking may have hepatic benefits are largely cross-sectional and used surrogate end points; and (iv) until further data from rigorous prospective studies become available, people with NAFLD should avoid alcohol of any type or amount.
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The red secTion 977 serum aminotransferases increased in stepwise fashion for increasing body mass index (ORs 1.6, 4.8, and 5.4 for body mass index categories <25, 25 to <30, and ≥30 kg/m 2 , respectively) (12). In another paper based on elderly people enrolled in the Rancho Bernardo Study, Loomba et al. have shown that people with a body mass index greater than 30 kg/m 2 and daily alcohol consumption of more than three drinks per day had towering adjusted odds ratios for elevated aspartate aminotransferase (OR 21) and alanine aminotransferase (OR 8.9) (13). The mechanism of the synergistic effect is not known but could in part be related to combined effects of alcohol and obesity on hepatic cytochrome P4502E1 and/or proinflammatory cytokines such as tumor necrosis factor-a (14) .
Despite the potential interactions between alcohol drinking and liver injury, emerging data suggest that non-heavy alcohol consumption may have paradoxical and favorable hepatic effects, presumably due to its effects on insulin sensitivity and other metabolic parameters. Suzuki et al. examined the cross-sectional relationship between alcohol consumption and hypertransaminasemia in 1,177 Japanese male subjects without hepatitis C or B virus or other chronic liver diseases (15) . In comparison with people with no alcohol consumption or minimal alcohol consumption (<70 g per week), heavy drinkers (drinking ≥280 g per week) had a significantly higher prevalence of hypertransaminasemia, but those with light (70-139 g per week) and moderate (140-279 g) did not. Interestingly, in a subgroup analysis stratified by age, light alcohol consumption in the younger (≤40 years) and moderate alcohol consumption in the older people (>41 years) were associated with a lower prevalence of hypertransaminasemia (15) . Dunn et al. examined the relationship between moderate consumption (≤7 drinks per week) of different types of alcoholic beverages and suspected NAFLD in 11,754 adults who participated in NHANES III. Moderate wine drinking, but not other types of alcoholic beverages, was independently associated with lower prevalence of suspected NAFLD (16) .
Two separate cross-sectional studies have reported that alcohol consumption may offer protection against the presence of fatty liver diagnosed by liver ultrasound in Japanese men. Gunji et al. have shown that light and moderate alcohol consumption was independently associated with lower prevalence of fatty liver in 5,599 Japanese men (17) . After adjustment for potential confounding variables, light (40-140 g per week) and moderate (1-280 g per week) alcohol consumption was inversely associated with prevalence of fatty liver (OR 0.82, 95% CI 0.68-0.99, and OR 0.75, 95% CI 0.61-0.92, respectively) (17). Moriya et al. examined the relationship between the prevalence of fatty liver and alcohol consumption in 4,957 Japanese men and 2,155 Japanese women (18) . After adjustment for metabolic covariates and exercise, alcohol consumption was independently and robustly associated with lower prevalence of fatty liver in men, but not in women. Interestingly, in this study the drinking frequency rather than the amount of alcohol consumed was an important factor in the protection offered by alcohol consumption against fatty liver.
The effect of alcohol consumption on liver histology in people firmly diagnosed with NAFLD has been described in three studies. Dixon et al. have shown that morbidly obese subjects with moderate alcohol consumption undergoing bariatric surgery had lower prevalence of steatohepatitis (OR 0.35, 95% CI 0.12-1.00), but this relationship did not persist after controlling for diabetes or insulin resistance (19) . In another study of 132 morbidly obese people undergoing bariatric surgery, there was no relationship between alcohol consumption and liver histology, but light to moderate alcohol consumption was inversely associated with insulin resistance (20) . A recent report from the National Institutes of Healthfunded NASH Clinical Research Network suggested that modest alcohol consumption is associated with favorable hepatic histology in NAFLD patients. After exclusion of NAFLD patients drinking ≥20 g per day, binge drinkers, and those with previous heavy alcohol consumption, as identified by the Alcohol Use Disorders Identification Test, the liver histology of 234 lifetime non-drinkers and 300 moderate drinkers with well-characterized NAFLD was compared. The odds of NASH and other histological features were analyzed by ordinal logistic regression adjusted for social, demographic, and lifestyle covariates. Compared with lifetime non-drinkers with NAFLD, people with NAFLD who reported moderate alcohol consumption had a significantly lower prevalence of NASH (OR 0.58, 95% CI 0.40-0.84, P = 0.004). Moderate drinkers also had a significantly lower prevalence of fibrosis (OR 0.58, 95% CI 0.42-0.81, P = 0.001), presence of ballooning (OR 0.67, 95% 0.48-0.94, P = 0.002), and portal inflammation (OR 0.68, 95% CI 0.47-0.99, P = 0.04) (21) .
The longitudinal studies examining the effect of alcohol consumption on the incidence of new fatty liver are very limited. In the study by Suzuki et al. mentioned above, 326 Japanese men with no evidence of hypertransaminasemia at baseline were followed up to 5 years, and moderate alcohol consumption was independently associated with lower incidence of hypertransaminasemia (adjusted OR 0.4, 95% CI 0.1-0.9, P = 0.02) (15) . To our knowledge, no prospective or longitudinal studies have examined the effect of ongoing alcohol consumption on disease severity or natural history in patients with established NAFLD or NASH.
If light to moderate alcohol consumption indeed is hepatoprotective, is it the alcohol or some other components in the alcoholic beverages that contribute to these suggested liver-protective effects? This question is difficult to answer, as most published studies do not take into account the types of alcoholic beverages subjects consumed. In the study by Dunn et al., the negative relationship between alcohol consumption and biochemical evidence of NAFLD was exclusively limited to moderate wine drinkers (16) . If this is true, then some components of wine aside from alcohol, such as natural polyphenols, may be playing a role in this phenomenon. In fact, in a mouse model of fatty liver, resveratrol improved insulin resistance and reduced the development of fatty liver (22) . The plausible mechanistic explanation may be that resveratrol inhibits SREBP-1c, a key transcription factor in lipogenesis, reducing oxidative damage, and ameliorates lipid peroxidation (22) .
The benefit of light or moderate alcohol consumption may not be limited to the liver but may also extend to cardiovascular health. Moderate alcohol drinking paradoxically correlates with elevated high-density lipoprotein cholesterol and lower cardiovascular disease (23, 24) . In the analysis of 490,000 people from the Cancer Prevention Study cohort, people who consumed one alcoholic drink daily had a decrease of 20% in overall mortality and 30-40% in cardiovascular mortality compared with non-drinkers (25) . In another study from Europe, people who consumed between three and five drinks of wine daily had a decreasing risk of death from all causes, including cardiovascular and cerebrovascular events, by ~50% compared with non-wine drinkers (24) . Patients with NAFLD are heavily enriched with metabolic disorders and are at significant risk for coronary artery disease (5, 6) . These epidemiological hints do bring up the question of whether light to moderate alcohol consumption may in fact improve long-term survival in subjects with NAFLD by reducing cardiovascular mortality.
Despite these potential benefits of light to moderate alcohol consumption, one must be aware of possible risks associated with light to moderate drinking, such as risks of breast and colon cancer (26, 27) . A recent study of subjects enrolled in the Nurses' Health Study found that increasing alcohol consumption was associated with an increase in breast cancer risk that was significant at levels as low as 5.0-9.9 g per day (equivalent to three to six drinks per week) (27) . Alcohol consumption may also be associated with a wide range of social problems, including road traffic injuries, and places some people at risk of progression to problem drinking. In light of these potential adverse effects, the World Health Organization recommends that alcohol consumption should not be used as a preventive strategy for other health benefits (28) .
In summary, heavy alcohol consumption has many harmful effects, including those on the liver, and should be discouraged regardless of whether a person has NAFLD or not. However, emerging epidemiological data suggest that light to moderate drinking may have favorable effects from a liver standpoint. But most studies are cross-sectional in nature and used surrogates such as aminotransferases and liver imaging. Furthermore, it is not clear whether cardiovascular and metabolic benefits of light to moderate alcohol consumption observed in the general population extend to those with NAFLD and NASH. There are emerging studies to suggest that even light alcohol consumption may increase the risk of cancers (e.g., breast and colon). Until further data from rigorously conducted prospective studies become available, we believe that people with NAFLD should avoid alcohol consumption of any type or amount.
